Your session is about to expire
← Back to Search
Radiopharmaceutical
18FDOPA PET/MRI for Hyperinsulinism (18FDOPA HI Trial)
Phase 2
Recruiting
Led By Ana Maria Arbelaez, MD, MSCI
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with confirmed hyperinsulinemic hypoglycemia, diagnosed by elevated insulin levels during hypoglycemia and/or response to glucagon stimulation
Subjects who failed pharmacological therapy with diazoxide or octreotide
Must not have
Cases in which surgery will not be considered by parents or guardians
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group
Summary
This trial will provide access to 18F-DOPA PET to patients with suspected focal lesions in the pancreas. The goal is to use 18F-DOPA PET/MRI to detect and localize these lesions, which will help guide surgery.
Who is the study for?
This trial is for patients with hyperinsulinemic hypoglycemia who can't be managed safely with standard treatments and need surgery. They must have high insulin levels during low blood sugar episodes or respond to glucagon stimulation, have failed therapy with diazoxide or octreotide, and provide informed consent.
What is being tested?
The study tests the use of a special imaging technique called 18F-Fluoro Dopa PET/MRI to find and pinpoint focal lesions in the pancreas causing hyperinsulinism before surgery at Washington University.
What are the potential side effects?
While not explicitly listed, potential side effects may include reactions related to the PET/MRI contrast agent used (like mild allergic reactions), discomfort from lying still during imaging, and exposure to radiation typical of such scans.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with low blood sugar due to high insulin levels.
Select...
I have tried diazoxide or octreotide for my condition without success.
Select...
My doctor recommends surgery because standard treatments for my low blood sugar haven't worked.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
Surgery is not an option for me as decided by my parents or guardians.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Increase Access to 18F-DOPA PET/MRI (or PET/CT) for patients with HI who failed medical therapy
Secondary study objectives
Accuracy of 18FDOPA PET/MRI to identify focal forms of hyperinsulinism that may be cured by surgery
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-Fluoro Dopa ImagingExperimental Treatment1 Intervention
single arm
Find a Location
Who is running the clinical trial?
Washington University School of MedicineLead Sponsor
1,991 Previous Clinical Trials
2,295,760 Total Patients Enrolled
St. Louis Children's HospitalOTHER
29 Previous Clinical Trials
87,722 Total Patients Enrolled
Ana Maria Arbelaez, MD, MSCIPrincipal InvestigatorWashington University School of Medicine
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Surgery is not an option for me as decided by my parents or guardians.I have been diagnosed with low blood sugar due to high insulin levels.I can safely undergo an MRI, or if not, a PET/CT scan.I have tried diazoxide or octreotide for my condition without success.My doctor recommends surgery because standard treatments for my low blood sugar haven't worked.
Research Study Groups:
This trial has the following groups:- Group 1: 18F-Fluoro Dopa Imaging
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger